title: Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials.
authors.affiliation: Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX; EEManasanch@mdanderson.org landgrec@mskcc.org.
authors.forename: Elisabet E
authors.initials: EE
authors.lastname: Manasanch
authors.affiliation: Myeloma Service, Memorial Sloan-Kettering Cancer Center, New York, NY;
authors.forename: Neha
authors.initials: N
authors.lastname: Korde
authors.affiliation: Multiple Myeloma Section, Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, USA.
authors.forename: Sham
authors.initials: S
authors.lastname: Mailankody
authors.affiliation: Multiple Myeloma Section, Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, USA.
authors.forename: Nishant
authors.initials: N
authors.lastname: Tageja
authors.affiliation: Multiple Myeloma Section, Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, USA.
authors.forename: Manisha
authors.initials: M
authors.lastname: Bhutani
authors.affiliation: Multiple Myeloma Section, Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, USA.
authors.forename: Mark
authors.initials: M
authors.lastname: Roschewski
authors.affiliation: Myeloma Service, Memorial Sloan-Kettering Cancer Center, New York, NY; EEManasanch@mdanderson.org landgrec@mskcc.org.
authors.forename: Ola
authors.initials: O
authors.lastname: Landgren
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D019468:Disease Management; D006801:Humans; D008991:Monitoring, Physiologic; D009101:Multiple Myeloma / Q000188:drug therapy*; D011379:Prognosis; D012307:Risk Factors
chemical_list: D000970:Antineoplastic Agents